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The androgen receptor (AR) and its signaling pathway play an important role in the development and progression of prostate cancer
(PCa). In the setting of primary treatment of PCa with radiotherapy (RT), where the AR can be expected to be of more importance,
studies evaluating the AR expression are lacking. The goal of this research is to evaluate AR protein expression in hormone-naive
PCa patients treated by RT and investigate its possible prognostic role. Primary biopsy samples of 18 patients treated with primary
RT were analyzed including the corresponding clinical information. AR protein expression of the tumor epithelium (with highest
Gleason pattern) and the surrounding stromawas quantified using the Quick score for steroid receptors.The differential expression
between epithelium and stroma, respectively, between tumor and normal tissue (ΔTumor −ΔBenign >2 versus ≤2), was predictive
for clinical progression-free survival in the biopsy samples (P = 0.014). Preliminary results of this research show already a promising
role of differential AR expression in predicting clinical relapse after PCa treatment with primary EBRT. Further research is needed
to validate these findings. Hopefully this can lead to a better understanding of PCa evolution and eventually lead to better therapy
strategies.
1. Introduction
The epithelial compartment of the prostate consists of basal
epithelial cells, intermediate cells, neuroendocrine cells, and
luminal secretory epithelial cells. Stroma, surrounding the
epithelial compartment, predominantly consists of connec-
tive tissue, smooth muscle cells, and fibroblasts. In the devel-
opment of the prostate, the epithelial budding is androgen-
dependent and requires intricate stromal-epithelial interac-
tions. Androgens act on the stroma to (indirectly) induce
prostate epithelial outgrowth during development and fur-
ther homeostasis in adulthood [1].
Prostate cells depend on androgens to stimulate growth,
function, and proliferation. In the 1940s, it was shown that
castration of men with prostate cancer (PCa) halted the dis-
ease progression [2]. Since then, therapy that suppresses the
androgen activity has been used as a systemic treatment of
advanced disease. Nowadays, androgen deprivation therapy
(ADT) is also used earlier in the disease progression or in
recurrent disease after definitive treatment, to reduce symp-
toms and prevent complications [1, 3, 4].
The AR is one of the most important gatekeepers of pros-
tate development and physiology. Due to the importance of
the AR pathway, alteration in its signaling can potentially
contribute to PCa development and/or progression [5–7].
The main mechanisms for both PCa development and
resistance to ADT are therefore AR dependent:
(i) changes in intratumoral ligand concentration (e.g., in
situ synthesis/metabolism),
(ii) AR overexpression (e.g., AR gene amplification) with
increased sensitivity to low ligand levels,
(iii) AR mutations with, for example, broadened ligand
specificity, hypersensitivity,
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(iv) ligand-independentARactivation, for example, splice
variants, activating mutations in the LBD, and cross
talk with other signaling pathways (IGF-1, EGF),
(v) increased transcriptional activity due to changes in
coregulatory molecules.
However, AR independent mechanisms such as the deregu-
lation of oncogenes (e.g., bcl-2, MDM2), tumor suppressor
genes (e.g., p53, PTEN), and the formation of fusion genes,
have also been described [6, 8, 9].
External beam radiotherapy (EBRT) is a standard treat-
ment for localized and locally advanced PCa [3]. The gold
standard technique for EBRT is intensity-modulated radio-
therapy (IMRT). In case of intermediate- or high-risk disease,
the use of concomitant and adjuvant ADT has shown to
be beneficial compared to RT alone [10]. Although all the
underlying mechanisms are not yet fully explained, ADT can
combat micrometastases during treatment and it acts as a
radiation sensitizer, making the PCa cells more susceptible
to the effects of exposure to ionizing radiation [11]. That is
why IMRT is combined with short-term ADT (4–6 months)
in case of intermediate-risk PCa and with long-term ADT
(18–36months) for high-risk disease [12].The optimal timing
and/or duration of ADT in combination with radiotherapy is
still a well discussed topic in the literature [13].
In the literature, several authors have tried to evaluate the
prognostic role ofAR expression in PCa after initial treatment
with radical prostatectomy (RP) [14, 15]. However, in the
setting of primary treatment of PCawith EBRT, where the AR
can be expected to be of more importance, studies evaluating
the AR expression are lacking.
The goal of this research is to evaluate AR protein expres-
sion in hormone-naive PCa patients treated by EBRT with
curative intent (with or without ADT). Also, to see if AR pro-
tein expression can act as a prognostic and/or predictive bio-
marker, before and after correction for known prognostic
factors such as PSA, Gleason score, and TNM-classification.
2. Material and Methods
A retrospective database was created with clinical PCa infor-
mation and follow-up of patients receiving primary treatment
for intermediate-, high-, and very-high-risk PCa. For this
pilot study a retrospective search was done in patient records
for PCa patients with primary diagnosis, lymph-node dissec-
tion, and EBRT treatment at our centre, starting frompatients
who had their treatment more than 4 years ago. When 18
patients were found, their clinical informationwas coded into
this database.
Approval by the local ethics committee was obtained for
this study (EC UZG 2011/718).
Biochemical progression after primary EBRTwas defined
as a rising PSA level by 2 ng/mL or more above the posttreat-
ment nadir (cf. Phoenix definition) [16]. Clinical recurrence
was defined as the development of a biopsy proven local
relapse or any lymphnode, bone, or visceralmetastasis shown
to progress on imaging.Death due to PCa alsowas considered
as clinical failure when a previous time point with clinical
failure was not stated.
From archived formalin-fixed, paraffin embedded tissue
samples 5 𝜇m slides were taken from the fragment with the
most aggressive tumor site (highest Gleason grade) and depa-
raffinized. A first slide was stained with haematoxylin-eosin
to confirm presence of tumor and Gleason pattern. A sec-
ond slide was stained according to the Masson’s trichrome
method, to easily differentiate collagen from smooth muscle
fibers. A third slide was stained with the monoclonal mouse
anti-human AR antibody (Clone AR441, Dako, Glostrup,
Denmark) to analyze AR expression.
Gleason score was determined according to the 2005
International Society of Urological Pathology (ISUP) recom-
mendations [17].
AR immunohistochemistry (IHC) samples were ana-
lyzed by minimal 2 readers, blinded to each other’s results
and blinded to the corresponding clinical information. AR
expression of the tumor epithelium (with highest Gleason
pattern) and the surrounding stromawas quantified using the
Quick score for steroid receptors, which evaluates the propor-
tion of cells staining and the staining intensity of these cells
[18]. When a representative portion of prostate glands on the
slide were free from tumor, benign epithelial cells and benign
stromal cells were also analyzed and scored in the sameman-
ner.This resulted in AR expression scores of 4 compartments:
tumor epithelium (TE), tumor stroma (TS), normal epithe-
lium (NE), and normal stroma (NS). In case of interobserver
Quick score discrepancy, the mathematical average was used.
Five prostatectomy specimens were analyzed before
beginning analysis of the biopsy specimen. These 5 patients
treated with primary RP progressed despite secondary
EBRT + ADT and died due to PCa.
Quick scores ranged 6 to 8 in tumor epithelium, 0 to 1 in
stroma surrounding tumor, and 2 to 6 in stroma surrounding
benign epithelium. To correct for the expression in NE and
surrounding NS, a new variable was considered in further
analysis (ΔTumor − ΔBenign). This is the absolute difference
in expression between epithelium and surrounding stroma,
this from, respectively, tumor with the highest Gleason pat-
tern and normal tissue.
Analysis of the formatted database was performed using
IBM SPSS v22.0. Next to descriptive statistics, comparative
statistics were performed by means of different hypothesis
tests. For categorical variables, the 𝜒2-test and the Fisher’s
exact test were used where appropriate. For continuous vari-
ables with comparison between two unpaired nonparametric
samples the Mann-Whitney 𝑈 test was used. Correlation
tests and other hypothesis tests were also performed. Relapse
analysis was performed using the Kaplan-Meier method and
log-rank test.
A𝑃 value< 0.05was considered as statistically significant.
Testing was performed two-sided. Graphical representations
and figures of the analysis were created using SPSS.
3. Results
Eighteen diagnostic tissue samples of patients treated by
primary EBRT were analyzed for AR protein expression. Of
these, 7 were treated with prostate only EBRT and 11 with
whole pelvis EBRT.
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Table 1: Comparison between clinical relapse group and group
without relapse during follow-up.
Parameter Clinical relapse(𝑛 = 11)
No relapse
during
follow-up
(𝑛 = 7)
Follow-up (months, median
[range])
After diagnosis 73 [46–153] 75 [60–101]
After primary EBRT 66 [40–148] 71 [55–95]
Age at diagnosis (𝑦, median
[range]) 64 [53–74] 63 [57–76]
Initial PSA (ng/ml, median
[range]) 30.1 [5.52–126.4] 13.7 [9.10–75]
PSA category (𝑛 (%))
PSA <10 ng/ml 2 (18.2) 1 (14.3)
PSA 10–20 ng/ml 3 (27.3) 3 (42.9)
PSA >20 ng/ml 6 (54.5) 3 (42.9)
N+ (yes (%)) 7 (63.6) 4 (57.1)
Gleason score (𝑛 (%))
≤6 1 (9.1) —
7 3 (27.3) 1 (14.3)
≥8 7 (63.6) 5 (71.4)
Gleason 5 component (yes
(%)) 5 (45.5) 5 (71.4)
Clinical T-stage (𝑛 (%))
cT1 1 (9.1) —
cT2 2 (18.2) 3 (42.9)
cT3 7 (63.6) 3 (42.9)
cT4 1 (9.1) 1 (14.3)
EAU risk classification (𝑛 (%))
Low-risk — —
Intermediate-risk 1 (9.1) 1 (14.3)
High-risk 2 (18.2) 1 (14.3)
Very-high-risk 8 (72.7) 5 (71.4)
Sixteen patients receivedADT and 2 patients did not. One
patient, with intermediate-risk PCa, received 6 months of
concomitant/adjuvant ADT and had no relapse documented
in a follow-up period of 55 months. The remainder received
long-term ADT treatment. No biopsy showed perineural
invasion.
Eleven patients (61%) in this group of mostly high- and
very-high-risk PCa patients had documented clinical relapse.
Three patients (16.67%) died during follow-up, 2 directly due
to PCa and one from colorectal cancer. Table 1 compares the
different parameters between patients with clinical relapse
versus no clinical relapse during follow-up (no statistical
significant differences between groups).
Quick scores differed between TE and NE and TS and NS
(resp., 𝑃 = 0.001 and 0.046). AR expression in TE was higher
compared to NE. On the other hand, surrounding TS had
lowerAR expression compared toNS.The absolute difference
Table 2: Comparison ofQuick scores and calculated values (median
[range]).
Location Clinical relapse(𝑛 = 11)
No relapse
during
follow-up
(𝑛 = 7)
Tumor tissue
Epithelium 8 [6–8] 8 [4–8]
Stroma 2 [0–7] 3 [2–5]
Benign tissue
Epithelium 6 [0–8] 7 [6–8]
Stroma 3 [0–5] 3.5 [3–5]
Epithelium − stroma
ΔTumor 6 [1–8] 5 [1–5]
ΔBenign 3 [−3–6] 3.5 [2–5]
ΔTumor − ΔBenign 3 [1–5] 1.5 [0–2]
ΔTumor/ΔBenign 2 [−0.33–6] 1.38 [1–2]
Tumor stroma − Benign stroma −1 [−3–4] −1/2 [−1–0]
Tumor stroma/Benign stroma 0.75 [0–2.33] 0.9 [0.67–1]
Whole pelvis
EBRT
(pN1)
Prostate only
EBRT
(pN0)
0 1 2 3 4 5
ΔTumor − ΔBenign
No relapse
No relapse
Clinical relapse
Clinical relapse
Figure 1: ΔTumor−ΔBenign in the relapse group versus no relapse
group, stratified according to pN stage.
between epithelium and stroma (ΔTumor − ΔBenign) was
highly significantly different between tumor and benign tis-
sue (𝑃 < 0.001). Table 2 compares theAR expression between
patients with clinical relapse versus patients with no clinical
relapse during follow-up. In one biopsy sample NS could not
be evaluated.
No significant differences could be found when compar-
ing Quick scores between the 2 groups. Only with ΔTumor −
ΔBenign seen as a continuous variable, the difference was
highly significant (𝑃 = 0.002).
All patients without clinical relapse during follow-up had
a ΔTumor − ΔBenign ≤2, compared to only 36.36% (𝑛 = 4)
in the relapse group. The differential expression (ΔTumor −
ΔBenign >2 versus ≤2) was associated with clinical relapse
within the biopsy samples (𝑃 = 0.035). Figure 1 shows the
differential expression stratified according to pN stage.
Kaplan-Meier analysis was performed to identify the
role of AR protein expression in predicting clinical relapse
after EBRT. For stratification, the Quick score of the stroma
surrounding tumor was grouped <2 (no expression) versus
≥2 (expression) and the differential expression (ΔTumor −
ΔBenign) >2 versus ≤2.
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Figure 2: Clinical progression-free survival subdivided by Quick score of the tumor stroma <2 versus ≥2, (a) for all biopsy samples and (b)
for all IHC samples (18 biopsies + 5 prostatectomy specimens).
In the 5 prostatectomy specimens analyzed before begin-
ning analysis of the biopsy specimen the AR protein expres-
sion was not different between TE (the highest Gleason
pattern) and NE (𝑃 = 0.257). However, TS had a lower
expression compared to NS (𝑃 = 0.043). The difference in
expression between epithelium and surrounding stroma was
higher when comparing tumor with benign tissue (𝑃 =
0.039). However, no correlation could bemadewith prognos-
tic factors or survival.
When looking at all analyzed samples (18 biopsy + 5 pro-
statectomy specimens), the (loss in) expression of AR in the
TS (Quick score <2 versus ≥2) was predictive for the clinical
progression-free survival rates (log-rank:𝑃 = 0.014). Kaplan-
Meier curves subdivided by TS AR expression are shown in
Figure 2.
The differential expression (ΔTumor−ΔBenign >2 versus
≤2) was also predictive for the clinical progression-free sur-
vival (log-rank:𝑃 = 0.017) in all samples (Figure 3), however,
not for overall survival after EBRT (𝑃 = 0.886).
Within the biopsy samples of the primary EBRT group,
only the differential expression remained significant for clin-
ical progression-free survival (log-rank: 𝑃 = 0.014, Figure 4).
Thedifferential AR expression between tumor and benign
tissue was a good predictor for clinical relapse in the group of
analyzed primary EBRT patients (AUC 0.902 [0.756–1], 𝑃 =
0.008, Figure 5).
log-rank: P = 0.017
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Figure 3: Clinical progression-free survival subdivided by
ΔTumor − ΔBenign >2 versus ≤2 for all samples (1 missing value of
normal stroma).
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Figure 4: Clinical progression-free survival subdivided by
ΔTumor − ΔBenign >2 versus ≤2 for all biopsy samples (1 missing
value of normal stroma).
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Figure 5: ROC-curve: representing the use of ΔTumor − ΔBenign
as a prediction method for clinical relapse.
4. Discussion
Several studies have already tried to evaluate the role of AR
protein in the curative treatment after RP, however, with
variable results and conclusions [14, 15, 18–20]. Differences
in tumor characteristics, specimens used, cohort size, tech-
niques evaluating AR, locations of AR expression measured,
and endpoints used make it very hard to compare results or
to draw definitive conclusions [21].
In this research, the main focus was on primary EBRT.
The benefit of adjuvant ADT to EBRT was previously proven
[22]. EBRT plays an important role in PCa treatment and
techniques have changed over time. A high percentage
of relapse (61%) was observed due to the high percent-
age of high- and very-high-risk PCa patients. Due to the
(very-)high-risk nature of this study population, comparison
of outcome with other results in the literature has to be done
carefully, taking into account all variables.
For analyzing the AR protein, several methods are avail-
able. In the setting of primary RT, PCa samples are mostly
biopsy specimen. AR expression was quantified by means of
IHC evaluation using the Quick score. This has proven to be
a reliable and easy applicablemethod,mainly in breast cancer
[23].Next to evaluating the presence or absence of expression,
it also enables to quantify the amount of expression (by
using the proportion of cells staining combined with the
staining intensity of these cells). Because of reports on the
importance of the surrounding stroma (see further and also
in the introduction), also stroma surrounding TE, as well as
NE and stroma were scored. Using this evaluation method
and using biopsy specimen, makes the results of this research
relevant and reproducible in daily clinical practice.
The importance of the AR pathway in normal prostate
development and functioning, as well as in PCa and further
progression, is an established fact. Several studies have tried
to assess the relationship between AR expression and the
clinical outcome of PCa, however, with conflicting results.
Li et al. reported that high levels of AR were associated
with increased proliferation andmarkers of aggressive disease
[19]. AR expression was correlated with the cT-stage, Gleason
score, and other prognostic factors such as SVI, ECE, and
lymph-node invasion. This research on 640 primary RP
specimen also showed that a high expression of AR was
predictive for a higher probability of recurrence. After correc-
tion by multivariate analysis, it showed to be an independent
prognostic indicator for biochemical recurrence-free survival
[19]. Next to an increased proliferation, research shows an
elevated AR protein expression in invasive PCa cells [24].
Even in CRPC cells the AR plays its role and AR expres-
sion is already elaborately researched. Knock-down of the AR
decreased the serum PSA value, inhibited tumor growth, and
resulted in tumor regression, in the castration resistant state
[25]. AR overexpression seems to sensitize the CRPC cells to
low levels of androgens [26]. The persistent AR axis output is
a target for novel therapies and raised questions to introduce
possible combination therapies [27].
Linja et al. reported in 2001 that AR gene amplification
was present in 31% at the hormone refractory state, but not
before hormone treatment. Their research showed also high
expression of the AR [28]. The selective pressure exerted by
ADThas been proposed to be the cause of AR gene amplifica-
tion and ARmutations [29]. Merson et al., however, reported
recently that focal amplification of the AR gene can be found
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in hormone-naive PCa. An increased gain of gene copy num-
ber was associated with a worse PCa-specific survival and
suggested a possible role of early total androgen ablation [30].
These findings show that the AR is evaluated in many
different settings and by many different methods. The review
of Tamburrino et al. suggested that these differences could
explain different results. They also suggested that the distinct
evaluation of the AR status (expression and activity) in dif-
ferent PCa compartments may help further research [21]. In
the 5 prostatectomy specimens analyzed for this report, AR
protein expression was not different between TE and NE.
Linking AR (over)expression to the worse prognosis of these
patients is therefore difficult. In the biopsy specimens, on the
other hand, AR expression was significantly higher in tumor
cells compared to NE.
During prostate carcinogenesis the surrounding stroma
undergoes elaborate changes by different mesenchymal-epi-
thelial interactions and paracrine influences. The amount of
smooth muscle cells reduces and cancer-associated fibrob-
lasts appear. The hormonal PCa development seems to be
independent of epithelial AR. The cross talk between tumor
and surrounding stroma is still not fully understood. Stromal
AR seems essential for epithelial proliferation control and is
able tomodulate the surrounding tumor promotingmicroen-
vironment [31–33].
Henshall et al. showed already in 2001 that the concurrent
overexpression of AR in the TE and loss of AR in the surrou-
nding stroma were associated with a poor clinical outcome
in PCa after RP [20]. Ricciardelli et al. reported it to be an
independent predictor of PSA relapse comparedwith iPSA or
Gleason score [14]. This indicates the potential role of loss in
AR expression of the stroma in the deregulation of prostate
epithelial cell proliferation. This is contrary to the findings
that a loss of stromal AR diminished the development of
prostatic intraepithelial neoplasia lesions [32].
Quantification and evaluation of the expression profile
of certain markers of reactive stroma have been proposed
to supply additional information to other prognostic factors
[34, 35]. It could assess the potential of early PCa progression
[36]. Several other authors established a link between low
levels of AR in tumor stroma, PCa aggressiveness, metastasis,
efficacy of castration therapy, and even survival after RP
[14, 18, 20, 37].
In this report, the AR protein expression also was eval-
uated before primary treatment with EBRT on PCa biopsy
specimen. Surrounding TS had lower AR expression com-
pared to NS (see Figure 2). Low stroma AR IHC staining
has previously been related to the loss of stroma smooth
muscle cells [18]. In normal tissue the AR protein expression
was variable. Therefore, a new parameter was introduced
(ΔTumor−ΔBenign), to correct for the AR expression profile
in normal tissue. Despite absence of statistical significant
differences in the distribution of several known clinical pro-
gnostic factors (see Table 1), there was interestingly a statisti-
cally significant difference for theΔTumor−ΔBenign param-
eter between patients with clinical relapse versus patients
without relapse during follow-up. It showed to be associated
with clinical relapse-free survival. Figure 1 suggests that this
marker may be even more helpful in pN0 disease. The
receiver operating characteristic (ROC) curve shows that
the differential AR expression could serve as an excellent
predictive marker for clinical relapse with a large area under
the curve (see Figure 5).
The reciprocal interactions between neoplastic cells and
supporting stromal cells are very complex. The tumor has its
own microenvironment with cancer-associated fibroblasts.
Epithelial-mesenchymal transition of epithelial cell enables
them to invade and to resist apoptosis and to disseminate
[38]. Stromal epigenetic changes can enhance the role of the
AR and be sufficient to induce PCa [38].
The different therapeutic possibilities in PCamake it even
more complex to understand all interactions between cancer
cells and their surroundings during and after treatment. ADT
has been shown to cause epithelial-mesenchymal transition
in both PCa and normal prostate tissue, using a feedback loop
involving the AR [39]. Arora et al. discussed the role of the
glucocorticoid receptor (GR) in substituting the role of the
AR after AR inhibition. Upregulation of theGRwas seen after
acute AR inhibition and was associated with clinical resis-
tance to enzalutamide. They suggested that corticosteroids
might even promote tumor progression when the tumor
expresses the GR and this resistance mechanism [40].
Next to the AR, other potential markers have been sug-
gested. Decreased PTEN expression has been associated with
an increased risk of recurrence in patients with clinically
localized PCa treated with RP, independent of known clinico-
pathological factors [41]. Also estrogen has been suggested to
play a role in the progression of PCa.Thevariations in steroid-
metabolizing enzymes during PCa control the bioavailability
of active steroid hormones in the prostate and may be crucial
in the regulation of growth [42].
Necrotic cell death releases proinflammatory signals into
the surrounding tissue microenvironment, in contrast to
apoptosis and autophagy [43]. Research of El-Saghire et al.
showed that low doses radiation with IMRT can induce
proinflammatory and prosurvival responses in PCa patients
[44]. After RT, expression of the AR, but also of estrogen
receptor-𝛼 and -𝛽, seems to have increased [45]. Research
of Polkinghorn et al. shows that AR signaling regulates DNA
repair in PCa [11]. This can be a potential mechanism of the
synergy between ADT and ionizing radiation. Adjuvant ADT
to EBRT has its synergistic effects by decreased tumor cell
hypoxia, decreased DNA repair, and decreased AR mediated
cell growth [11].
An important shortcoming is the small sample size
of analyzed AR IHC specimens. Further analysis of other
available specimens and clinical data was not done for this
pilot study. However, the displayed results are already very
promising.
Further sample analysis is needed to validate if the
differential expression of AR protein expression can be of
importance in the primary EBRT setting.This research report
emphasizes the role of the AR in this setting due to the link
between AR, DNA repair, and ADT. The goal is to see if AR
protein expression can act as a prognostic marker (of patient
outcome independent of given therapy) and/or a predictive
marker (of the possible response to a specific therapy) in the
setting of EBRT with or without ADT [46].
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The role of different hormones and the alterations in PCa
progression have to be further investigated. This will help to
explore benefits of different treatments and/or even play its
role in personalized medicine. The interaction with stroma
should be taken into account in cell culture research [47].
Targeting the tumor microenvironment and the stromal AR
could be attractive as a therapeutic strategy because of its
critical involvement in PCa [33, 48].
5. Conclusion
The setting of primary EBRT can be very interesting to eval-
uate the prognostic and predictive role of AR protein expres-
sion, especially due to interaction of ADT (often given con-
comitant/adjuvant with EBRT) and the AR. The differences
in AR expression observed in this research suggest that a
changed AR expression of epithelium and its surrounding
stroma could be of importance.
Preliminary results show already a promising role of
differential AR expression in predicting clinical relapse after
treatment of PCa with primary EBRT. Further validation of
these findings is necessary.
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